KoreaTimes

Entertainment
& Arts

Sports

World

SCMP
Asia

Video

Photos

Site Map E-paper Subscribe Register LogIn
Site Map E-paper Subscribe Register LogIn

Business

Bio

Mon, October 3, 2022 | 09:59

Korean biotech firms show off capabilities in Europe

HLB, Celltrion, NeoImmuneTech and other Korean biotech companies confirmed their competitiveness in Europe as they showcased their new drug development capabilities at the European Society for Medical Oncology (ESMO) Congress, an annual medical oncology fair to share the latest developments in cancer research, they said Tuesday. This year's ESMO Congress was held in Paris for...

Baek Byung-yeul | 2022-09-13 16:46

HLB's liver cancer treatment shows longest overall survival

Local biotech company HLB said its liver cancer treatment candidate Rivoceranib showed over 22 months of overall survival in its Phase 3 clinical trials, the longest in any liver cancer treatment, the company said, Thursday. The company said it plans to hold a meeting with the U.S. Food and Drug Administration (FDA) to apply for approval for new drugs, given the effectiveness...

Baek Byung-yeul | 2022-09-08 14:20

Celltrion receives approval to sell anticancer biosimilar Vegzelma in Europe

Korean biopharmaceutical firm Celltrion said Friday it has received an approval to sell its anticancer biosimilar Vegzelma in Europe.

2022-08-19 15:52

Samsung Biologics, C&T invest in US biotech firm Senda Biosciences

An investment fund created by Samsung Biologics and Samsung C&T invested $15 million into U.S.-based biotechnology company Senda Biosciences as part of their efforts to foster core technology required to develop next-generation biopharmaceuticals, Samsung Biologics said on Wednesday. Samsung Biologics said the Life Science Fund, jointly formed by itself and Samsung C&T, decid...

Baek Byung-yeul | 2022-08-17 16:16

Yoon promises to foster bio-health industry

President Yoon Suk-yeol vowed Wednesday to foster the bio-health industry into a key national strategic industry as he met with health experts at a medical research facility.

2022-07-27 14:13

Daesang to set up joint venture with China Sinopharm International

Daesang Life Science, a Korean manufacturer of health functional foods, said Wednesday it has inked a letter of intent with China Sinopharm International to set up a joint venture in a bid to make forays into the Chinese market.

2022-07-27 14:13

Matica Bio aims to join global top 5 cell & gene therapy producers by 2030

Matica Biotechnology, a U.S. subsidiary of CHA Biotech, revealed its goal to join the global top five manufacturers of cell and gene therapy and generate sales of over 1 trillion won ($762.8 million) by 2030, its CEO said Thursday. “The global cell and gene therapy's CDMO (contract development and manufacturing organization) market is expected to grow by more than 20 percent ...

Baek Byung-yeul | 2022-07-21 16:10

Korean disease institute, Moderna agree to collaborate in SFTS mRNA vaccine development

Korea's state-run National Institute of Infectious Diseases (NIID) said Wednesday it has reached an agreement with Moderna, a U.S. biotech company, to cooperate in the development of a messenger RNA (mRNA) vaccine candidate for severe fever and thrombocytopenia syndrome (SFTS).

2022-07-20 13:18

Split from GSK, Haleon seeks to solidify consumer healthcare leadership

Consumer healthcare company Haleon was officially launched on Monday (U.K. time) after completing its spinoff from GSK, its Korean unit said Tuesday. Haleon is a global leading company in the consumer healthcare markets of 170 countries, selling numerous well-known brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, Parodontax and Centrum.

Baek Byung-yeul | 2022-07-19 16:34

Moderna says committed to making Omicron-adaptive vaccine candidate available in Aug.

Moderna, a U.S. biotech company specializing in messenger RNA (mRNA) coronavirus vaccines, is committed to making its new bivalent vaccine candidate available next month, which reportedly demonstrates a superior antibody response against Omicron variants.

2022-07-19 15:29

1 2 3 4 5

CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.